glp-1 mitochondria Glucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulation Glucagon-like Peptide 1 Receptor Activation

In February 2022, the 46-year-old from New Jersey had prediabetes and high blood pressure when his doctor asked if he had considered trying a GLP-1 medication

Glucocorticoids decrease the production of glucagon-like peptide-1 at the transcriptional level in intestinal L-cells

A reasonable schedule includes comprehensive metabolic panel, complete blood count, vitamin B12, vitamin D, iron studies, and thyroid function every three to six months during active treatment

While the metabolic impacts of these medications are well documented, interest is now growing in their potential effects beyond glucose control, including neuropsychiatric outcomes